A design for phase II testing of anticancer agents within a phase III clinical trial

Daniel J Schaid, James N. Ingle, Sam Wieand, David L. Ahmann

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)107-118
Number of pages12
JournalControlled Clinical Trials
Volume9
Issue number2
DOIs
StatePublished - 1988

Fingerprint

Phase III Clinical Trials
Antineoplastic Agents
Sample Size
Random Allocation
Patient Selection
Clinical Trials
Breast Neoplasms
Therapeutics

Keywords

  • phase II Anticancer agents
  • phase III survival comparison
  • Randomized design

ASJC Scopus subject areas

  • Pharmacology

Cite this

A design for phase II testing of anticancer agents within a phase III clinical trial. / Schaid, Daniel J; Ingle, James N.; Wieand, Sam; Ahmann, David L.

In: Controlled Clinical Trials, Vol. 9, No. 2, 1988, p. 107-118.

Research output: Contribution to journalArticle

Schaid, Daniel J ; Ingle, James N. ; Wieand, Sam ; Ahmann, David L. / A design for phase II testing of anticancer agents within a phase III clinical trial. In: Controlled Clinical Trials. 1988 ; Vol. 9, No. 2. pp. 107-118.
@article{cd5d63e62c234392a95d86b973718c46,
title = "A design for phase II testing of anticancer agents within a phase III clinical trial",
abstract = "A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.",
keywords = "phase II Anticancer agents, phase III survival comparison, Randomized design",
author = "Schaid, {Daniel J} and Ingle, {James N.} and Sam Wieand and Ahmann, {David L.}",
year = "1988",
doi = "10.1016/0197-2456(88)90032-3",
language = "English (US)",
volume = "9",
pages = "107--118",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - A design for phase II testing of anticancer agents within a phase III clinical trial

AU - Schaid, Daniel J

AU - Ingle, James N.

AU - Wieand, Sam

AU - Ahmann, David L.

PY - 1988

Y1 - 1988

N2 - A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.

AB - A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.

KW - phase II Anticancer agents

KW - phase III survival comparison

KW - Randomized design

UR - http://www.scopus.com/inward/record.url?scp=0023879701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023879701&partnerID=8YFLogxK

U2 - 10.1016/0197-2456(88)90032-3

DO - 10.1016/0197-2456(88)90032-3

M3 - Article

C2 - 3396362

AN - SCOPUS:0023879701

VL - 9

SP - 107

EP - 118

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 2

ER -